Literature DB >> 22586007

A multidimensional index and staging system for idiopathic pulmonary fibrosis.

Brett Ley1, Christopher J Ryerson, Eric Vittinghoff, Jay H Ryu, Sara Tomassetti, Joyce S Lee, Venerino Poletti, Matteo Buccioli, Brett M Elicker, Kirk D Jones, Talmadge E King, Harold R Collard.   

Abstract

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease with an overall poor prognosis. A simple-to-use staging system for IPF may improve prognostication, help guide management, and facilitate research.
OBJECTIVE: To develop a multidimensional prognostic staging system for IPF by using commonly measured clinical and physiologic variables.
DESIGN: A clinical prediction model was developed and validated by using retrospective data from 3 large, geographically distinct cohorts.
SETTING: Interstitial lung disease referral centers in California, Minnesota, and Italy. PATIENTS: 228 patients with IPF at the University of California, San Francisco (derivation cohort), and 330 patients at the Mayo Clinic and Morgagni-Pierantoni Hospital (validation cohort). MEASUREMENTS: The primary outcome was mortality, treating transplantation as a competing risk. Model discrimination was assessed by the c-index, and calibration was assessed by comparing predicted and observed cumulative mortality at 1, 2, and 3 years.
RESULTS: Four variables were included in the final model: gender (G), age (A), and 2 lung physiology variables (P) (FVC and Dlco). A model using continuous predictors (GAP calculator) and a simple point-scoring system (GAP index) performed similarly in derivation (c-index of 70.8 and 69.3, respectively) and validation (c-index of 69.1 and 68.7, respectively). Three stages (stages I, II, and III) were identified based on the GAP index with 1-year mortality of 6%, 16%, and 39%, respectively. The GAP models performed similarly in pooled follow-up visits (c-index ≥71.9). LIMITATION: Patients were drawn from academic centers and analyzed retrospectively.
CONCLUSION: The GAP models use commonly measured clinical and physiologic variables to predict mortality in patients with IPF.

Entities:  

Mesh:

Year:  2012        PMID: 22586007     DOI: 10.7326/0003-4819-156-10-201205150-00004

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  288 in total

1.  Broad Therapeutic Efficacy of Nintedanib in Idiopathic Pulmonary Fibrosis.

Authors:  Athol U Wells; Ivan O Rosas
Journal:  Am J Respir Crit Care Med       Date:  2016-01-15       Impact factor: 21.405

2.  The ILD-GAP risk prediction model performs poorly in myositis-associated interstitial lung disease.

Authors:  Rebeccah M Brusca; Iago Pinal-Fernandez; Kevin Psoter; Julie J Paik; Jemima Albayda; Christopher Mecoli; Eleni Tiniakou; Andrew L Mammen; Lisa Christopher-Stine; Sonye Danoff; Cheilonda Johnson
Journal:  Respir Med       Date:  2019-02-21       Impact factor: 3.415

3.  Relevance analysis of clinical and lung function parameters changing and prognosis of idiopathic pulmonary fibrosis.

Authors:  Xueren Li; Shouchun Peng; Luqing Wei; Zhenhua Li
Journal:  Int J Clin Exp Med       Date:  2014-12-15

4.  Body mass index-percent forced vital capacity-respiratory hospitalization: new staging for idiopathic pulmonary fibrosis patients.

Authors:  Tomoo Kishaba; Hiroaki Nagano; Yuichiro Nei; Shin Yamashiro
Journal:  J Thorac Dis       Date:  2016-12       Impact factor: 2.895

Review 5.  Managing Idiopathic Pulmonary Fibrosis: Which Drug for Which Patient?

Authors:  Conal Hayton; Nazia Chaudhuri
Journal:  Drugs Aging       Date:  2017-09       Impact factor: 3.923

6.  Clinical characteristics in patients with asymmetric idiopathic pulmonary fibrosis.

Authors:  Sean J Callahan; Meng Xia; Susan Murray; Kevin R Flaherty
Journal:  Respir Med       Date:  2016-08-31       Impact factor: 3.415

7.  MicroRNA-144-3p targets relaxin/insulin-like family peptide receptor 1 (RXFP1) expression in lung fibroblasts from patients with idiopathic pulmonary fibrosis.

Authors:  Harinath Bahudhanapati; Jiangning Tan; Justin A Dutta; Stephen B Strock; John Sembrat; Diana Àlvarez; Mauricio Rojas; Benedikt Jäger; Antje Prasse; Yingze Zhang; Daniel J Kass
Journal:  J Biol Chem       Date:  2019-02-01       Impact factor: 5.157

8.  BAL Cell Gene Expression Is Indicative of Outcome and Airway Basal Cell Involvement in Idiopathic Pulmonary Fibrosis.

Authors:  Antje Prasse; Harald Binder; Jonas C Schupp; Gian Kayser; Elena Bargagli; Benedikt Jaeger; Moritz Hess; Susanne Rittinghausen; Louis Vuga; Heather Lynn; Shelia Violette; Birgit Jung; Karsten Quast; Bart Vanaudenaerde; Yan Xu; Jens M Hohlfeld; Norbert Krug; Jose D Herazo-Maya; Paola Rottoli; Wim A Wuyts; Naftali Kaminski
Journal:  Am J Respir Crit Care Med       Date:  2019-03-01       Impact factor: 21.405

Review 9.  Biomarkers in idiopathic pulmonary fibrosis.

Authors:  Yingze Zhang; Naftali Kaminski
Journal:  Curr Opin Pulm Med       Date:  2012-09       Impact factor: 3.155

10.  Patterns of interstitial lung disease and mortality in rheumatoid arthritis.

Authors:  Jorge A Zamora-Legoff; Megan L Krause; Cynthia S Crowson; Jay H Ryu; Eric L Matteson
Journal:  Rheumatology (Oxford)       Date:  2017-03-01       Impact factor: 7.580

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.